| Literature DB >> 29875354 |
Takeshi Saraya1, Kazuhito Fukuoka2, Hideto Maruno3, Yoshinori Komagata2, Masachika Fujiwara4, Shinya Kaname2, Yoshihiro Arimura2, Akira Yamada2, Hajime Takizawa5.
Abstract
BACKGROUND Rheumatoid arthritis tenosynovitis is difficult to discriminate from non-tuberculous tenosynovitis on the basis of radiological and pathological findings. CASE REPORT A 74-year-old woman with a 4-year history of rheumatoid arthritis was referred to our hospital to undergo treatment for uncontrollable tenderness and swelling in her right third metacarpophalangeal joint, right wrist, and left knee joint. In the previous year, she underwent surgery at a local hospital for the swelling in her right metacarpophalangeal joint, the information of which was not known precisely, but the swelling subsided in due course after an operation. We treated the patient with infliximab (monthly intravenous infusions of 150 mg), but 2 months later, she complained of exacerbation of the swelling in her right third metacarpophalangeal joint and right wrist, and fluid discharge that contained Mycobacterium intracellulare. After synovectomy and aggressive debridement in the palmar side of the right wrist, she was diagnosed as having granulomatous tenosynovitis caused by the M. intracellulare infection and abundant rice body formation in the right carpal tunnel area. We considered the rice bodies inside and outside the bursa, along with a history of tenosynovitis exacerbation after initiation of infliximab therapy (tumor necrosis factor alpha inhibitor [TNFi]), to be related to the M. intracellular infection. CONCLUSIONS Tenosynovitis caused by atypical mycobacteria is uncommon and usually affects the hand or wrist. Therefore, for early diagnosis, mycobacterial infection should be considered in cases of indolent chronic granulomatous tenosynovitis, especially in RA cases that recur after TNFi therapy is started.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29875354 PMCID: PMC6020799 DOI: 10.12659/AJCR.908785
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Figure 1.Right wrist swelling (A) with erosion of the radius (B, arrow).
Figure 2.Swelling of the right middle finger (A) and right wrist (B) with an induration in the flexor side of the right wrist and palm. Serous fluid discharge from the right wrist is also visible (B, arrow). The right wrist swelling and protruding induration recurred after 5 years (C) and subsided again after 1.5 years of treatment (D).
Figure 3.The sagittal (A) and axial (B) T2-weighted fat-suppression magnetic resonance images of the right hand show low-intensity debris (size: 3 mm) in the carpal tunnel area and high-intensity subperiosteal cystic change or intraosseous edema (C).
Figure 4.The histological analysis result shows synovial papillary proliferation (A, arrow) that enclosed a large quantity of fibrin (A, asterisk) and epithelioid granulomas (B) with inflammatory cell infiltration. The abundant rice bodies from the debridement specimens exhibit a reticular structure that was mainly composed of fibrin (C).
Infectious tenosynovitis after treatment for rheumatoid arthritis using tumor necrosis factor alpha inhibitors: a summary of the reported cases.
| 2010 | F | 82 | Psoriatic arthritis | NA | Infliximab | MTX | 3 | ST, AZM | |
| F | 59 | RA | 3 years | Etanercept | MTX corticosteroid injection | 3 | RFB, CAM, LVFX | ||
| M | 65 | Seronegative RA | < Several months | Etanercept Infliximab | Prednisone MTX plaquenil | 3 | AZM, EB, CAM | ||
| 2010 | F | 47 | RA, lupus, pulmonary | < Several months | Etanercept Infliximab | Prednisone | Unknown | 2 | CAM, linezolid, moxifloxacin |
| F | 77 | RA | < Several years | Infliximab | Plaquenil, MTX | <3 | Voriconazole | ||
| 2008 | F | 48 | Seronegative RA | <3 years | Leflunomide | MTX corticosteroid injection | 3 | RFP, CAM, EB | |
| 2002 | M | 61 | RA | >4 months | Etanercept Infliximab | Corticosteroid injection | 1 | CAM |
NA – not available; RA – rheumatoid arthritis; MTX – methotrexate; ST – trimethoprim/sulfamethoxazole; AZM – azithromycin; RFB – rifabutin; CAM – clarithromycin; LVFX – levofloxacin.